Pharmacologic therapies for acute cardiogenic shock

Current Opinion in Cardiology

Volumn 29, Issue 3, 2014, Pages 250-257

  Nativi Nicolau, Jose ^a,b   Selzman, Craig H ^a   Fang, James C ^a   Stehlik, Josef ^a,b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

Author keywords

inotropes; shock; vasopressors

Indexed keywords

ADRENALIN; CALCIUM; CALCIUM SENSITIZER; DIURETIC AGENT; DOBUTAMINE; DOPAMINE; HYPERTENSIVE FACTOR; LEVOSIMENDAN; MILRINONE; NORADRENALIN; PHENYLEPHRINE; PLACEBO; VASOPRESSIN; ANTIINFLAMMATORY AGENT; CARDIOTONIC AGENT; VASOCONSTRICTOR AGENT;

ASSISTED CIRCULATION; CARDIOGENIC SHOCK; CLINICAL TRIAL; HEMODYNAMICS; HUMAN; INFLAMMATION; MORTALITY; PRIORITY JOURNAL; REVIEW; CLINICAL TRIAL (TOPIC); COMPARATIVE EFFECTIVENESS; DRUG EFFECTS; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; SHOCK, CARDIOGENIC;

ANTI-INFLAMMATORY AGENTS; CARDIOTONIC AGENTS; CLINICAL TRIALS AS TOPIC; COMPARATIVE EFFECTIVENESS RESEARCH; DIURETICS; HEMODYNAMICS; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); SHOCK, CARDIOGENIC; VASOCONSTRICTOR AGENTS;

EID: 84899480139     PISSN: 02684705     EISSN: 15317080     Source Type: Journal    
DOI: 10.1097/HCO.0000000000000057     Document Type: Review

References (51)

1. Nohria A, Lewis E, Stevenson LW. Medical management of advanced heart failure. JAMA 2002; 287:628-640.
2. Reynolds HR, Hochman JS. Cardiogenic shock: current concepts and improving outcomes. Circulation 2008; 117:686-697.
3. Stevenson LW, Pagani FD, Young JB, et al. INTERMACS profiles of advanced heart failure: the current picture. J Heart Lung Transplant 2009; 28:535-541. Description of the INTERMACS profile of advanced heart failure.
4. Colucci WS, Wright RF, Jaski BE, et al. Milrinone and dobutamine in severe heart failure: differing hemodynamic effects and individual patient responsiveness. Circulation 1986; 73:3175-3183.
5. Abraham WT, Adams KF, Fonarow GC, et al. In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an Analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). J Am Coll Cardiol 2005; 46:57-64.
6. Oliva F, Latini R, Politi A, et al. Intermittent 6-month low-dose dobutamine infusion in severe heart failure: DICE multicenter trial. Am Heart J 1999; 138:247-253.
7. O'Connor CM, Gattis WA, Uretsky BF, et al. Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan international randomized survival trial (FIRST). Am Heart Journal 1999; 138:78-86.
8. Teerlink JR, Sliwa K, Opie LH. Heart failure. In: Opie LH, Gersh BJ, editors. Drugs for the heart, 8th ed. Philadelphia: Elsevier Inc.; 2013.
9. Cuffe MS, Califf RM, Adams KF Jr, et al. Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure I. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 2002; 287:1541-1547.
10. Follath F, Cleland JG, Just H, et al. Investigators of the Levosimendan Infusion versus Dobutamine study. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 2002; 360:196-202.
11. Moiseyev VS, Poder P, Andrejevs N, et al. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, doubleblind study (RUSSLAN). Eur Heart J 2002; 23:1422-1432.
12. Mebazaa A, Nieminen MS, Packer M, et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA 2007; 297:1883-1891.
13. Packer M, Colucci W, Fisher L, et al. Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure. J Am Coll Cardiol Heart Failure 2013; 1:103.
14. Zobel C, Reuter H, Schwinger RH. Treatment of cardiogenic shock with the Ca2\+ sensitizer levosimendan [in German]. Medizinische Klinik 2004; 99:742-746.
15. Benlolo S, Lefoll C, Katchatouryan V, et al. Successful use of levosimendan in a patient with peripartum cardiomyopathy. Anesth Analg 2004; 98:822-824.
16. Lehmann A, Lang J, Boldt J, et al. Levosimendan in patients with cardiogenic shock undergoing surgical revascularization: a case series. Med Sci Monit 2004; 10:MT89-MT93.
17. Garcia-Gonzalez MJ, Dominguez-Rodriguez A, Ferrer-Hita JJ. Utility of levosimendan, a new calcium sensitizing agent, in the treatment of cardiogenic shock due to myocardial stunning in patients with ST-elevation myocardial infarction: a series of cases. J Clin Pharmacol 2005; 45:704-708.
18. Delle Karth G, Buberl A, Geppert A, et al. Hemodynamic effects of a continuous infusion of levosimendan in critically ill patients with cardiogenic shock requiring catecholamines. Acta Anaesthesiol Scand 2003; 47:1251-1256.
19. Follath F, Franco F, Cardoso JS. European experience on the practical use of levosimendan in patients with acute heart failure syndromes. Am J Cardiol 2005; 96:80G-85G.
20. Westfall TC, Westfall DP. Adrenergic agonists and antagonists. In: Laurence L, Burnton KLP, editors. Goodman & Gilmans's: the pharmacolocigal basis of therapeutics. 12th ed. New York: McGraw-Hill Companies, Inc.; 2011.
21. Aviado DM Jr, Schmidt CF. Effects of sympathomimetic drugs on pulmonary circulation: with special reference to a new pulmonary vasodilator. J Pharmacol Exp Ther 1957; 120:512-527.
22. De Backer D, Biston P, Devriendt J, et al. Comparison of dopamine and norepinephrine in the treatment of shock. New Engl J Med 2010; 362:779-789.
23. Harrison DC, Pirages S, Robison SC, Wintroub BU. The pulmonary and systemic circulatory response to dopamine infusion. Br J Pharmacol 1969; 37:618-626.
24. Chen HH, Anstrom KJ, Givertz MM, et al. Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial. JAMA 2013; 310:2533-2543.
25. Biaggioni I, Robertson D. Adrenoceptor agonists & sympathomimetic drugs. In: Katzung B, Masters S, Trevor A, editors. Basic and clinical pharmacology. 12th ed. McGraw-Hill companies; 2010.
26. Barrett LK, Singer M, Clapp LH. Vasopressin: mechanisms of action on the vasculature in health and in septic shock. Crit Care Med 2007; 35:33-40.
27. Lauzier F, Levy B, Lamarre P, Lesur O. Vasopressin or norepinephrine in early hyperdynamic septic shock: a randomized clinical trial. Intensive Care Med 2006; 32:1782-1789.
28. Patel BM, Chittock DR, Russell JA, Walley KR. Beneficial effects of short-term vasopressin infusion during severe septic shock. Anesthesiology 2002; 96:576-582.
29. Morelli A, Ertmer C, Rehberg S, et al. Continuous terlipressin versus vasopressin infusion in septic shock (TERLIVAP): a randomized, controlled pilot study. Crit Care 2009; 13:R130.
30. Dunser MW, Mayr AJ, Ulmer H, et al. Arginine vasopressin in advanced vasodilatory shock: a prospective, randomized, controlled study. Circulation 2003; 107:2313-2319.
31. Russell JA, Walley KR, Singer J, et al. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 2008; 358:877-887.
32. Jolly S, Newton G, Horlick E, et al. Effect of vasopressin on hemodynamics in patients with refractory cardiogenic shock complicating acute myocardial infarction. Am J Cardiol 2005; 96:1617-1620.
33. Wallace AW, Tunin CM, Shoukas AA. Effects of vasopressin on pulmonary and systemic vascular mechanics. Am J Physiol 1989; 257:H1228-1234.
34. Argenziano M, Choudhri AF, Oz MC, et al. A prospective randomized trial of arginine vasopressin in the treatment of vasodilatory shock after left ventricular assist device placement. Circulation 1997; 96:2286-2290.
35. Albright TN, Zimmerman MA, Selzman CH. Vasopressin in the cardiac surgery intensive care unit. Am J Crit Care 2002; 11:326-330.
36. Hochman JS, Sleeper LA, Webb JG, et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock. N Engl J Med 1999; 341:625-634.
37. Marenzi G, Assanelli E, Campodonico J, et al. Acute kidney injury in STsegment elevation acute myocardial infarction complicated by cardiogenic shock at admission. Crit Care Med 2010; 38:438-444.
38. Reilly RF, Jackson EK. Regulation of renal function and vascular volume. In: Laurence B, John L, Keith P, editors. Goodman & Gilmans's the pharmacological basis of therapeutics. 12th ed. New York: McGraw-Hill Companies, Inc.; 2011.
39. Opie LH, Victor RG, Kaplan NM. Diuretics. In: Opie LH, Gersh BJ, editors. Drugs for the heart, 8th ed. Philadelphia: Elsevier Inc.; 2013.
40. Biddle TL, Yu PN. Effect of furosemide on hemodynamics and lung water in acute pulmonary edema secondary to myocardial infarction. Am J Cardiol 1979; 43:86-90.
41. Felker GM, Lee KL, Bull DA, et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med 2011; 364:797-805.
42. Jentzer JC, DeWald TA, Hernandez AF. Combination of loop diuretics with thiazide-type diuretics in heart failure. J Am Coll Cardiol 2010; 56:1527-1534.
43. Channer KS, McLean KA, Lawson-Matthew P, Richardson M. Combination diuretic treatment in severe heart failure: a randomised controlled trial. Br Heart J 1994; 71:146-150.
44. Hochman JS. Cardiogenic shock complicating acute myocardial infarction: Expanding the paradigm. Circulation 2003; 107:2998-3002.
45. Landry DW, Oliver JA. The pathogenesis of vasodilatory shock. N Engl J Med 2001; 345:588-595.
46. Akiyama K, Suzuki H, Grant P, Bing RJ. Oxidation products of nitric oxide, NO2 and NO3, in plasma after experimental myocardial infarction. J Mol Cell Cardiol 1997; 29:1-9.
47. Akiyama K, Kimura A, Suzuki H, et al. Production of oxidative products of nitric oxide in infarcted human heart. J Am Coll Cardiol 1998; 32:373-379.
48. TRIUMPH Investigators, Alexander JH, Reynolds HR, et al. Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock: the TRIUMPH randomized controlled trial. JAMA 2007; 297:1657-1666.
49. Shanmugam G. Vasoplegic syndrome: the role of methylene blue. Eur J Cardiothoracic Surg 2005; 28:705-710.
50. Leyh RG, Kofidis T, Struber M, et al. Methylene blue: the drug of choice for catecholamine-refractory vasoplegia after cardiopulmonary bypass? J Thorac Cardiovasc Surg 2003; 125:1426-1431.
51. Levin RL, Degrange MA, Bruno GF, et al. Methylene blue reduces mortality and morbidity in vasoplegic patients after cardiac surgery. Ann Thorac Surg 2004; 77:496-499.